T CELL REDIRECTING BISPECIFIC ANTIBODIES FOR THE TREATMENT OF EGFR POSITIVE CANCERS

The present invention relates to bispecific antibodies which bind to CD3 and EGFR simultaneously. This class of antibody has been demonstrated by the inventors to be useful in the treatment of EGFR tumors by redirecting T cells and forming an immune synapse between activated T cells and EGFR expressing tumor cells, leading to increased levels of killing of EGFR expressing tumor cells. In particular the present invention relates to CD3×EGFR bispecific antibodies selected from the group comprising CD3×EGFR_SF1 (SEQ ID NO: 4, 5 and 6), CD3×EGFR_SF3 (SEQ ID NO: 7, 2 and 8), CD3×EGFR_SF4 (SEQ ID NO: 4, 5 and 9), CD3×EGFR_SD1 (SEQ ID 10 NO: 1, 2 and 10) and CD3×EGFR_SD2 (SEQ ID NO: 11, 10 and 2).